Home
Sitemap
Glossary
Contact
Products
Investors
Careers
Sustainability
Media
About Us
country websites
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
Chile
Czech Republic
Denmark
Estonia
Finland
Germany
Greece
Gulf countries
India
Ireland
Italy
Lundbeck Pharmaceuticals Italy
Japan
Korea
Latvia
Mexico
Netherlands
Norway
Pakistan
Poland
Russia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
United States of America
Venezuela
Quick access to
Our products
Select
Cipralex
Ebixa
Azilect
Serdolect
Circadin
Our therapy areas
Select
Depression
Anxiety
Alzheimer's disease
Parkinson's disease
Schizophrenia
Insomnia
Other Lundbeck sites
Select
CNSForum
Cipralex.com
Ebixa.com
Azilect.com
Serdolect.com
DepNet.com
DementiaNet
Brainexplorer
Patient Support Programme (iCan)
Psychotropics online
Sleep problems
My PD info
What are you looking for?
Annual report 2008
Order printed material
Employee profiles
Patient information
Pipeline
Partnering with us
Lundbeck A/S (LUN)
96.80 DKK +0.45
at 16:59:52
OMX Copenhagen 20 (OMXC20)
345.43 +6.04
at 16:59:52
Latest releases
The European Commission opens proceedings
07-Jan-2010
Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia - planning for continued clinical work
18-Dec-2009
View all releases
H. Lundbeck A/S
Ottiliavej 9
DK-2500 Copenhagen Valby
Phone +45 3630 1311
Fax +45 3630 1940
information@lundbeck.com
The specialist in psychiatry and pioneer in neurology
Disclaimer